Fusion Biopsy

Global Fusion Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Fusion Biopsy estimated at US$714.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Transrectal Biopsy Route, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$640.9 Million by the end of the analysis period. Growth in the Transperineal Biopsy Route segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$194.7 Million While China is Forecast to Grow at 10.3% CAGR

The Fusion Biopsy market in the U.S. is estimated at US$194.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Fusion Biopsy Market – Key Trends & Drivers Summarized

Why is Fusion Biopsy Revolutionizing Cancer Diagnostics?

Fusion biopsy has emerged as a groundbreaking advancement in cancer diagnostics, particularly in the detection of prostate cancer, due to its superior accuracy and ability to target suspicious lesions with precision. Unlike traditional biopsy methods, which rely solely on transrectal ultrasound (TRUS) imaging, fusion biopsy integrates magnetic resonance imaging (MRI) with real-time ultrasound to enhance lesion visualization and improve sampling accuracy. This combination significantly reduces the risk of false-negative results and unnecessary repeat biopsies, addressing a long-standing challenge in cancer diagnostics. Given the increasing prevalence of prostate cancer and the need for early and accurate detection, fusion biopsy is rapidly gaining adoption in leading hospitals, cancer centers, and diagnostic laboratories worldwide.

The growing awareness among healthcare providers about the limitations of conventional biopsy techniques has further fueled the demand for MRI-ultrasound fusion biopsy. Clinicians and researchers are increasingly advocating for its use in cases where PSA (prostate-specific antigen) levels are elevated but standard TRUS-guided biopsies yield inconclusive results. Additionally, advancements in imaging software and AI-driven diagnostic tools have enhanced the accuracy of lesion detection, making fusion biopsy a more reliable diagnostic tool for various forms of cancer, including kidney, liver, and breast malignancies. As precision medicine continues to evolve, the role of fusion biopsy in improving early cancer detection and personalized treatment planning is becoming more prominent.

How is Technology Enhancing the Accuracy and Efficiency of Fusion Biopsy?

Recent innovations in medical imaging and biopsy technology have significantly improved the efficiency and accuracy of fusion biopsy procedures. AI-powered image analysis has enhanced lesion detection capabilities, reducing the risk of sampling errors and improving diagnostic confidence. Real-time 3D imaging has further optimized the biopsy process by allowing clinicians to precisely map tumor locations and adjust needle trajectories accordingly. Additionally, robotic-assisted biopsy systems are being integrated with fusion biopsy platforms to increase precision, minimize patient discomfort, and reduce procedure time.

The development of cloud-based biopsy management software has also streamlined data storage, analysis, and remote collaboration among pathologists and oncologists. These digital platforms enable seamless sharing of biopsy results, facilitating multidisciplinary cancer care and second-opinion consultations. Moreover, the integration of machine learning algorithms into fusion biopsy systems is allowing for the automated identification of cancerous tissues, reducing the need for invasive repeat procedures. As the adoption of minimally invasive diagnostic techniques continues to grow, fusion biopsy is expected to become a standard of care in oncological diagnostics, replacing conventional biopsy methods that often yield inconclusive or unreliable results.

Which Medical Specialties and Healthcare Institutions Are Driving Demand for Fusion Biopsy?

Urology remains the primary medical specialty driving demand for fusion biopsy, as prostate cancer diagnosis accounts for the majority of its applications. Leading hospitals, specialty cancer clinics, and diagnostic imaging centers are actively investing in fusion biopsy systems to improve patient outcomes and reduce misdiagnosis rates. Additionally, academic research institutions and clinical trial organizations are utilizing fusion biopsy technology to study new biomarkers and evaluate targeted therapies, expanding its application beyond standard cancer diagnostics.

Beyond prostate cancer, the adoption of fusion biopsy is growing in nephrology, gastroenterology, and hepatology for the detection of kidney, liver, and pancreatic tumors. Breast cancer research is also benefiting from the technology, as fusion biopsy is enabling more precise tissue sampling in cases where mammographic and ultrasound findings are inconclusive. The expansion of telemedicine and remote diagnostics has further facilitated access to fusion biopsy expertise in underserved regions, where specialized oncological imaging was previously limited. With rising cancer incidence rates and increasing investments in advanced diagnostic technologies, the demand for fusion biopsy across multiple medical specialties is expected to surge.

What Key Factors Are Driving Market Growth?

The growth in the fusion biopsy market is driven by several factors, including advancements in imaging technology, increasing cancer incidence rates, and the growing emphasis on early and accurate diagnosis. The widespread adoption of AI-assisted imaging and robotic biopsy systems has improved procedural efficiency, reducing the likelihood of sampling errors and improving patient outcomes. Additionally, the expansion of telemedicine and cloud-based diagnostic platforms has made fusion biopsy more accessible to healthcare institutions worldwide, particularly in regions with limited oncological expertise.

Regulatory approvals for fusion biopsy devices and the integration of new biomarkers into diagnostic protocols are also fueling market expansion. The shift toward minimally invasive cancer diagnostics, coupled with rising investments in personalized medicine, has further strengthened the demand for fusion biopsy. Additionally, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating the development of next-generation biopsy systems that enhance precision, automation, and AI-driven decision-making. As healthcare systems continue to prioritize early cancer detection, fusion biopsy is expected to play an increasingly pivotal role in the future of precision oncology.

SCOPE OF STUDY:

The report analyzes the Fusion Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Biopsy Route (Transrectal Biopsy Route, Transperineal Biopsy Route); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Ambulatory Care Centers End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Artemis
• Biobot Surgical
• BK Medical
• D&K Technologies
• Eigen
• Esaote
• Focal Healthcare
• GE Healthcare
• Hitachi Medical Systems
• innoMedicus
• KOELIS
• MedCom
• Medtronic
• Philips Healthcare
• Profound Medical
• Siemens Healthineers
• SonaCare Medical
• Toshiba Medical Systems Corporation
• United Medical Systems
• UroNav

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.